Today at #ASGCT26, Serif Biomedicines is sharing preclinical data from our Modified DNA platform. DNA has long held significant therapeutic potential, but realizing that potential depends on addressing several scientific requirements at once, including immune sensing, intracellular activity, delivery, tolerability, and durable expression. The data we are presenting today span each of these areas, with results across non-human primates, liver-directed expression, and in vivo immune cell programming. Read the press release for more: https://lnkd.in/eDFNyMgC
About us
Serif Biomedicines is pioneering Modified DNA as a new class of biotechnology. Founded in 2021 within Flagship Labs, the innovation foundry of Flagship Pioneering, Serif integrates nucleic acid chemistry, synthetic biology, delivery science, and artificial intelligence to enable programmable, scalable, durable, and redosable DNA medicines. The company's initial focus is on genetically defined diseases and reprogramming the immune system.
- Website
-
https://serifbiomedicines.com/
External link for Serif Biomedicines
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
Employees at Serif Biomedicines
Updates
-
Serif Biomedicines has been selected for an oral presentation at the ASGCT 2026 Annual Meeting, where the company will share preclinical data supporting Modified DNA as a potential new therapeutic modality. The findings highlight our progress in creating DNA medicines: IV administered Modified DNA-LNPs are well-tolerated in NHPs with minimal innate immune stimulation and, when combined with mRNA co-factors, in rodents drives high, durable gene expression in the liver and T cells. For more about #ASGCT26 visit: https://lnkd.in/dHgkVjV
-
-
DNA is biology’s core information layer, but it has remained out of reach as a practical medicine. Our CEO Jacob Rubens joined Decoding Bio for its first Substack Live to discuss how Serif's Modified DNA could unlock the long-standing challenges, and opportunity, for DNA medicines.
Serif Biomedicines has launched with $50M from Flagship Pioneering to turn modified DNA into a new class of medicine. CEO and founder Jacob Rubens joined me for Decoding Bio's first Substack Live to discuss what they are building. We cover: - Why DNA has struggled as a therapeutic despite decades of effort - The two barriers that have blocked the field: the immune system attacks it, and it has to reach the nucleus - What five years of stealth work has demonstrated in primates - Why delivery remains the most challenging unsolved problem - The potential programs and therapeutic areas
Scaling Bio 008: Serif Biomedicines' Jake Rubens on Turning Modified DNA into a New Class of Medicine
decodingbio.substack.com
-
We are proud to launch Serif Biomedicines, a new Flagship-founded company pioneering Modified DNA. Across biotechnology, enduring companies have been built by turning core layers of biology into practical therapeutic platforms. DNA is the next frontier. Serif’s Modified DNA platform is intended to enable medicines that are programmable, scalable, durable, and redosable, opening new possibilities across genetic disease and immune programming. Serif reflects Flagship’s belief that when a foundational layer of biology becomes engineerable, new therapeutic categories can emerge. https://lnkd.in/ekDEdDDK